Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMendaza, Saioa-
dc.contributor.authorFernández Irigoyen, Joaquín-
dc.contributor.authorSantamaría, Enrique-
dc.contributor.authorArozarena, Imanol-
dc.contributor.authorGuerrero-Setas, David-
dc.contributor.authorZudaire, Tamara-
dc.contributor.authorGuarch, Rosa-
dc.contributor.authorVidal-Bel, August-
dc.contributor.authorSalas, José Santos-
dc.contributor.authorMatias-Guiu, Xavier-
dc.contributor.authorAusín, Karina-
dc.contributor.authorGil, Carmen-
dc.contributor.authorHernández Alcoceba, Rubén-
dc.contributor.authorMartín Sánchez, Esperanza-
dc.description.abstractCervical cancer (CC) is managed mainly using subjective and conventional methods. Research about the molecular mechanisms of micro-RNA-877-3p (miR-877-3p) in other cancer types revealed that it interacts with events that are important for CC. Our aim was to understand the role of miR-877-3p in CC. We observed that it was overexpressed in cervical tumors compared with benign lesions, and that it promoted CC cell migration and invasion by modulating cytoskeletal protein folding, which potentiated the effects caused by paclitaxel, one of the most common therapeutic drugs used in CC. We demonstrated a functional link between miR-877-3p and one of its predicted targets, ZNF177. The expression and subcellular location of ZNF177 objectively distinguished two CC entities and predicted poor outcome in the most aggressive form. Therefore, the understanding of the molecular mechanisms driven by miR-877-3p provides useful tools for CC clinical management, currently lacking of molecular biomarkers and targeted therapies. No therapeutic targets and molecular biomarkers are available in cervical cancer (CC) management. In other cancer types, micro-RNA-877-3p (miR-877-3p) has been associated with events relevant for CC development. Thus, we aimed to determine miR-877-3p role in CC. miR-877-3p levels were examined by quantitative-PCR in 117 cervical lesions and tumors. Effects on CC cell proliferation, migration, and invasion were evaluated upon anti-miR-877-3p transfection. miR-877-3p dependent molecular mechanism was comprehensively explored by proteomics, dual-luciferase reporter assay, western blot, and immunohistochemistry. Cervical tumors expressed higher miR-877-3p levels than benign lesions. miR-877-3p promoted CC cell migration and invasion, at least partly by modulating cytoskeletal protein folding through the chaperonin-containing T-complex protein 1 complex. Notably, miR-877-3p silencing synergized with paclitaxel. Interestingly, miR-877-3p downregulated the levels of an in silico-predicted target, ZNF177, whose expression and subcellular location significantly distinguished high-grade squamous intraepithelial lesions (HSILs) and squamous cell carcinomas of the cervix (SCCCs). Cytoplasmic ZNF177 was significantly associated with worse progression-free survival in SCCC. Our results suggest that: (i) miR-877-3p is a potential therapeutic target whose inhibition improves paclitaxel effects; (ii) the expression and location of its target ZNF177 could be diagnostic biomarkers between HSIL and SCCC; and (iii) cytoplasmic ZNF177 is a poor-prognosis biomarker in SCCC.-
dc.format.extent26 p.-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofCancers, 2021, vol. 13, num. 7-
dc.rightscc by (c) Mendaza et al., 2021-
dc.subject.classificationCàncer de coll uterí-
dc.subject.classificationMarcadors bioquímics-
dc.subject.otherCervix cancer-
dc.subject.otherBiochemical markers-
dc.titleUnderstanding the Molecular Mechanism of miR-877-3p Could Provide Potential Biomarkers and Therapeutic Targets in Squamous Cell Carcinoma of the Cervix-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
cancers-13-01739-v2.pdf3.12 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons